Novo to supply drugs to Greece, faces fines; AZ deemed likely to prevail on Crestor patent;

> Novo Nordisk (NOVOb.CO) will supply Greece with its drugs as normal after authorities proposed a new pricing formula, but could face fines for pulling them off the market, Greece's drug watchdog said. Report

> Barclays raised its rating on AstraZeneca (UK:AZN, AZN) to overweight, saying it believes the company stands a 60 percent to 65 percent chance of victory in the U.S. patent dispute around cholesterol treatment Crestor. Report

> Generic companies hoping to market a cheap copy of GlaxoSmithKline's (GSK.L) best-selling inhaled lung drug Advair might have wait until 2012 before winning a green light from regulators in Europe. Report

> Only 38 percent of European biopharmaceutical companies feel that they have the ability to influence market access stakeholders, according to new research. Report

> GlaxoSmithKline received a second rebuff in as many days from Britain's NICE when the healthcare cost watchdog ruled its platelet-boosting drug Revolade was not worth using on the state health service. Report

> Harbin Pharmaceutical (HPG), the Chinese buyer of Pfizer's swine vaccine unit, is preparing workshops and technicians to take over the production line, the company announced. Report

> A drug commonly used to treat gout may help patients with chronic kidney disease keep their condition in check and reduce the risk of heart problems, Spanish scientists said. Report

> Hospira said that European Union regulators have approved its drug Nivestim as a treatment for certain side effects of chemotherapy. Report

Biotech News

 @FierceBiotech: Covance plans 300 hires for Indiana campus. Report | Follow @FierceBiotech

 @JohnCFierce: Sharing data on failed Alzheimer's trials makes a lot of sense. It's also cool to see biopharma companies working together. | Follow @JohnCFierce

> Big Pharma coalition will pool data on failed Alzheimer's drugs. Report

> Precision Therapeutics gets $33M to support ChemoFx. Story

> UCB ups stake in oncology partner. Item

> BMS, Pfizer wrap apixaban stroke trial early on positive verdict. Results

> Inotek gathers $18M as it plots PhII trials. News

> FDA panel hands Novartis lopsided endorsement of oral MS therapy. Article

And Finally... Why aren't more patients getting the shingles vaccine? Report